Integrated voice collaboration, best-in-class compliant communication and the power of connectivity showcased at Symphony’s Innovate New York 2022
mehr
Ergebnis der Suchanfrage nach Bristol-Myers Squibb
Newsrooms
Inhalte
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
98 Treffer
SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy ...
mehrMerck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to EUR 605 million in development ...
mehrDGAP-Adhoc: BB BIOTECH AG: Product approvals and solid company results lead the biotech sector higher
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): 9-month figures BB BIOTECH AG: Product approvals and solid company results lead the biotech sector higher 20-Oct-2017 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely ...
mehrGSK's Global HIV Business ViiV Healthcare Completes Transactions to Acquire Bristol-Myers Squibb's R&D HIV Assets
London (ots/PRNewswire) - GlaxoSmithKline plc (LSE: GSK) today announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has completed two previously announced transactions with Bristol-Myers Squibb to acquire its late-stage HIV ...
mehrEuropean Liver Patients Association (ELPA)
European Liver Patients Association (ELPA) Launches New Digital Guide for People Diagnosed with Hepatitis C
Brussels (ots/PRNewswire) - There are approximately nine million people in Europe infected with the hepatitis C virus, with tens of thousands of new cases diagnosed each year - and this trend is rising.[1] Currently there is no single online resource where people diagnosed with hepatitis C can go to find out more ...
mehr
CORRECTION - Merck: Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
Darmstadt, Germany (ots/PRNewswire) - In the news release, "Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan" issued on 13 Feb 2015 06:33 GMT, by Merck over PR Newswire, we are advised by a representative of the company that in the third paragraph ...
mehrMerck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in Japan
Darmstadt, Germany (ots/PRNewswire) - - Not intended for US- and UK-based media - Merck and Bristol-Myers Squibb to end co-promotion of Erbitux in Japan, with full promotional responsibilities transferring to Merck Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Programme Announces New Winning Projects Designed to Investigate Novel Ways to Cure Viral Diseases
Paris (ots/PRNewswire) - The Partnering for Cure faculty of experts today announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV). As ...
mehrPutting the Patient First: Merck Serono to Present Data That Embodies the ESMO 2014 Theme of 'Precision Medicine in Cancer Care'
Darmstadt, Germany (ots/PRNewswire) - Not intended for US- and UK-based media ESMO 2014 Abstract #: Physician biomarker survey: 1080O_PR; Erbitux: CRYSTAL: 541P; LASCCHN: 993PD; DIRECT: 996P; Pipeline: pimasertib: 443O; c-Met: 1333TiP, 450PD, 744TiP, 745TiP; further pipeline: 772P, 507PD, 1235P - New research ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
SHE Day: The Strong, HIV Positive, Empowered Women (SHE) Faculty and Bristol-Myers Squibb Celebrated Four Years of SHE, a First-of-Its Kind Programme Addressing the Specific Challenges Faced by Women Living with HIV in Europe
Paris (ots/PRNewswire) - - The SHE network continues to expand across Europe to empower and educate women living with HIV and their health care providers - More than 60 SHE units, multidisciplinary teams based in HIV clinics and dedicated to women with HIV, have been implemented in 18 countries 'SHE' (Strong, HIV ...
mehrMerck to Collaborate with Sysmex Inostics on a Blood-Based RAS Biomarker Test
Darmstadt, Germany (ots/PRNewswire) - - Development and commercialization agreement on blood-based RAS biomarker mutation status test for (metastatic) colorectal cancer (mCRC) - This non-invasive, fast and easy-to-perform diagnostic test is expected to provide a real-time reflection of a patient's RAS mutation status to help guide clinical decision making in mCRC Merck ...
mehr
Merck Announces New Retrospective Analysis Shows Significant Clinical Benefit in Overall Survival for Metastatic Colorectal Cancer Patients with RAS Wild-Type Tumors Receiving Erbitux plus FOLFIRI
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract Number: 3506 - In a retrospective analysis of the Phase III CRYSTAL* study, which assessed RAS tumor status, significant clinical benefit was observed in mCRC patients with RAS wild-type tumors receiving Erbitux plus FOLFIRI, compared with FOLFIRI alone - No ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure(TM) Virology Research Programme
Paris (ots/PRNewswire) - Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European scientific initiative supporting breakthrough research and facilitating greater collaboration and knowledge-sharing with the virology community In advance of this year's International Liver CongressTM 2014 in London, ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb-Sponsored Partnering for Cure(TM) Program Names Three European Award Winners for Research Projects Focused on Cure in Viral Diseases
Paris (ots/PRNewswire) - First-ever, Europe-wide scientific initiative designed to accelerate virology clinical research & transform clinical outcomes for patients Three European virology researchers were awarded research grants this week based on their proposed research projects to investigate novel ways to cure ...
mehrEuropean Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Darmstadt, Germany (ots/PRNewswire) - - The European Commission's approval is based on the CHMP positive opinion - Label update comes in response to new biomarker data obtained from the OPUS study Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the ...
mehrMerck Serono Announces CHMP Positive Opinion to Update Erbitux Metastatic Colorectal Cancer Labeling to Patients with RAS Wild-type Tumors
Darmstadt, Germany (ots/PRNewswire) - - CHMP recommendation comes in response to new biomarker data obtained from the OPUS study Merck Serono, the biopharmaceutical division of Merck, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe
Paris, France (ots/PRNewswire) - Yervoy, an innovative immuno-oncology therapy that has demonstrated durable long-term survival in some patients,[1],[2] is now approved for use in previously-untreated patients Bristol-Myers Squibb today announced that the European Commission (EC) has approved YERVOY(R) (ipilimumab) ...
mehr
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy(TM) (Ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma
Princeton, New Jersey (ots/PRNewswire) - - In this pooled analysis of 12 studies, a plateau in the survival curve begins at approximately three years, with some patients followed for up to ten years - Three-year estimated survival rate of 22% observed in patients treated with ipilimumab - Findings are based on ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis
Paris (ots/PRNewswire) - AMPLE Study results highlighted during a press conference at the European League Against Rheumatism (EULAR) Annual congress - Year 2 data shows similar efficacy between ORENCIA plus methotrexate (MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma
Princeton, New Jersey (ots/PRNewswire) - Intended only for European media based outside of the UK - 53% response rate observed in patients receiving 1 mg/kg nivolumab plus 3 mg/kg Yervoy concurrently (n= 9 of 17), the dose used in the Phase 3 trial; of these responders all experienced at least 80% tumor shrinkage ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection
Princeton, New Jersey (ots/PRNewswire) - - This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option - Investigational regimen involves three different classes of direct-acting antivirals (DAAs) - an NS5A replication complex inhibitor, an NS3 protease inhibitor and an NS5B ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic Myeloid Leukaemia in 15 European Countries
Paris (ots/PRNewswire) - My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company today announced the introduction of "My CML Life", a disease awareness website for patients with chronic myeloid leukaemia (CML). In recognition of ...
mehrBristol-Myers Squibb Foundation
Bristol-Myers Squibb Foundation's SECURE THE FUTURE® Programme Announces New Findings Confirming Grandmothers Against Poverty and AIDS (GAPA) Has Positive Impact on Mitigating HIV/AIDS Impact in the Community
Cape Town, South Africa (ots/PRNewswire) - Survey finds empowerment programme helps 57 percent of respondents reduce socioeconomic impact of HIV/AIDS by providing tools to reduce poverty and emotional burden of disease New research presented today at the first Africa Regional Conference on Gerontology and Geriatrics ...
mehr
Bristol-Myers Squibb GmbH & Co. KGaA
Subcutaneous Formulation of ORENCIA® (abatacept) Approved by European Commission
Paris (ots/PRNewswire) - Proven biologic is first therapy available in both subcutaneous and intravenous formulations for adults with moderate to severe active rheumatoid arthritis Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA(R) (abatacept), in combination with ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
New Four- and Five-Year Survival Data for YERVOY® (ipilimumab) in Treatment-Naïve and Previously-Treated Metastatic Melanoma Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
Princeton, New Jersey (ots/PRNewswire) - - Long-Term Follow Up From Phase 3 Study (024) Demonstrated That 19.0 Percent of Treatment-Naïve Patients Who Received YERVOY at Investigational Dose of 10 mg/kg Plus Dacarbazine (DTIC) Were Alive at Four Years vs. 9.6 Percent of Patients Treated with DTIC Alone - Few New ...
mehrBristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Three-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced results from the 3-year follow-up of the DASISION trial, which show that first-line treatment with SPRYCEL(R) 100 mg results infaster ...
mehrBristol-Myers Squibb & Otsuka Pharmaceutical Europe Ltd.
Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
ORENCIA® ? (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Paris (ots/PRNewswire) - ? - ORENCIA demonstrated comparable efficacy to HUMIRA based on a non-inferiority endpoint for ACR20 response at 1 year - Kinetics of response for ACR20, 50 and 70, and inhibition of radiographic progression were generally comparable over 12 months - AMPLE is the first head-to-head study in ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
Paris (ots/PRNewswire) - - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] today announced that the company will present 18 abstracts on abatacept ...
mehr
1234Nächste